Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Drug

Neurophth Biotechnology Completes Enrollment and Dosing in US Clinical Study for ND4-LHON Gene Therapy

Fineline Cube Feb 20, 2024

Neurophth Biotechnology Ltd, a leading gene therapy specialist based in China, has announced the completion...

Company Deals

Biocytogen Pharmaceuticals Inks Antibody Evaluation Deal with Gilead Sciences

Fineline Cube Feb 20, 2024

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced an antibody...

Company Deals

Evopoint Biosciences Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization

Fineline Cube Feb 20, 2024

Evopoint Biosciences Co., Ltd., a Suzhou-based biopharmaceutical company, has announced the successful completion of a...

Company Drug

Phanes Therapeutics’ PT886 Receives CDE Approval for Clinical Trials in Advanced Solid Tumors

Fineline Cube Feb 20, 2024

Sino-US biotechnology company Phanes Therapeutics Inc. has announced that it has received clinical trial approval...

Company Drug

ImmunoTech Biopharm Gets NMPA Green Light for Clinical Study of aT19 Injection for B-ALL

Fineline Cube Feb 20, 2024

ImmunoTech Biopharm Ltd (HKG: 6978), a specialist in chimeric antigen receptor T-cell (CAR-T) therapies based...

Policy / Regulatory

Beijing, Tianjin, and Hebei Release Draft Proposal for Updated Drug Clinical Trial Inspection Standards

Fineline Cube Feb 20, 2024

The medical products administration bureaus of Beijing, Tianjin, and Hebei province have released a draft...

Company Drug

AstraZeneca’s Tagrisso Wins Expanded FDA Approval for EGFR-mutated NSCLC

Fineline Cube Feb 20, 2024

UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has received a new indication approval from the...

Company Drug

Innovent Biologics’ IBI311 Achieves Primary Endpoint in Phase III Study for Thyroid Eye Disease

Fineline Cube Feb 20, 2024

Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced that its...

Policy / Regulatory

China’s CDE Issues Guiding Principles for ADC Research and Evaluation

Fineline Cube Feb 20, 2024

China’s Center for Drug Evaluation (CDE) has issued a notification outlining the “Guiding Principles for...

Company Legal / IP Policy / Regulatory

GSK and Peers Respond to FTC Criticism, Withdraw Patent Listings from US Orange Book

Fineline Cube Feb 20, 2024

Three pharmaceutical companies, including the UK’s GSK (NYSE: GSK), have responded to the Federal Trade...

Company Deals

Astellas Pharma Partners with Kelonia Therapeutics to Advance CAR-T Cell Therapies

Fineline Cube Feb 19, 2024

Astellas Pharma Inc. (TYO: 4503) has announced a strategic research collaboration and licensing agreement with...

Company Drug

Denali Therapeutics Faces Setback as ALS Trial Fails to Meet Primary Endpoint

Fineline Cube Feb 19, 2024

Denali Therapeutics (NASDAQ: DNLI) has announced disappointing results from a Phase II trial of its...

Policy / Regulatory

China’s NMPA Releases 77th Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Feb 19, 2024

The National Medical Products Administration (NMPA) has released the 77th batch of reference drugs for...

Policy / Regulatory

GSK’s Avodart Receives NMPA Approval to Resume Sales in China from September

Fineline Cube Feb 19, 2024

The National Medical Products Administration (NMPA) has released a notification announcing that GlaxoSmithKline’s (GSK) Avodart...

Policy / Regulatory

National Health Commission Notification Signals New Poliovirus Containment Measures

Fineline Cube Feb 19, 2024

The National Health Commission (NHC) has issued a notification announcing the establishment of the National...

Policy / Regulatory

China’s NHC Approves 2023 Large Medical Equipment Configuration Licenses, Targets Cancer Treatment

Fineline Cube Feb 19, 2024

The National Health Commission (NHC) has granted approval for the Class A large medical equipment...

Company Drug

Hainan Poly Pharm Wins FDA Nod for Generic Version of UCB’s Vimpat

Fineline Cube Feb 19, 2024

Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...

Company Policy / Regulatory

US Lawmakers Call for Sanctions Against WuXi AppTec and WuXi Biologics Over National Security Concerns

Fineline Cube Feb 19, 2024

US politicians have intensified their opposition to China’s biotech industry, with Congressmen and Senators sending...

Company

Novartis Begins Review of 70% Stake in Indian Unit, Strategic Options Under Consideration

Fineline Cube Feb 18, 2024

Novartis (NYSE: NVS) has initiated a review process concerning its 70.68% stake in Novartis India...

Company Medical Device

Boao Yiling Life Care Center Launches Innovative Dental Technologies Under Pilot Medical Policy

Fineline Cube Feb 18, 2024

Boao Yiling Life Care Center has successfully completed the inaugural use of a dental comprehensive...

Posts pagination

1 … 454 455 456 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.